Osteogenic effect of polymethyl methacrylate bone cement with surface modification of lactoferrin

https://doi.org/10.1016/j.jbiosc.2021.04.006Get rights and content

Polymethyl methacrylate (PMMA) bone cement is a commonly used filling material in orthopedic surgery. Its good and stable performances make it the most widely used in all kinds of bone cement. With the advancement of the application and research of PMMA bone cement by surgeons, its disadvantages such as non-degradation and non-bioactivity are gradually exposed. In recent years, the biological functions of lactoferrin (LF) have been gradually explored, especially its role in promoting osteogenesis. In this study, LF was modified on the surface of solidified PMMA bone cement (LF/PMMA bone cement) by physical/chemical mixed modification and verified by cytological experiments in vitro. In vitro studies have implicated that PMMA bone cement modified with LF can improve the attachment, expansion, proliferation, extracellular matrix secretion and osteogenic differentiation of mouse preosteoblasts (MC3T3-E1) cells, indicating biocompatibility. This experiment provides a novel insight for improving the biological activity of PMMA bone cement and lays a foundation for broadening the clinical application of PMMA bone cement.

Section snippets

Materials

The PMMA bone cement used in this study came from Mendec Spine Resin (Tecres S.P.A., Verona, Italy), a diameter of 1.00 cm and a thickness of 0.02 cm were used for surface characterization and in vitro assessment in 24-well tissue culture plates. Tris (hydroxy-methyl), p-nitrophenyl phosphate (PNPP), 1-ethyl-3-(3-dimethylaminopropkl) carbodiimide hydrochloride (EDC), Alizarin Red-S, dapi staining (DAPI), cell counting kit-8 (CCK-8) and LF (origin: human milk, cat. no. L4894) were purchased from

Results and discussion

PMMA bone cement has attracted more and more attention because of its good mechanical properties and stable chemical performances. However, PMMA bone cement is a bioinert material with no biological activity, which restricts its clinical application. Therefore, scholars have made various attempts to improve the biological activity of PMMA bone cement in order to make up for its defects and expand its clinical application. In the aspect of improving the biological activity of PMMA, single

Acknowledgments

This study was supported by Scientific Research Project of Jilin Provincial Department of Education (JJKH20211172KJ). The authors declare that they have no conflicts of interest.

References (39)

  • M.P. Prabhakaran et al.

    Electrospun nanostructured scaffolds for bone tissue engineering

    Acta Biomater.

    (2009)
  • M. Kouhi et al.

    Poly L lysine-modified PHBV based nanofibrous scaffolds for bone cell mineralization and osteogenic differentiation

    Appl. Surf. Sci.

    (2018)
  • D. Naot et al.

    Molecular mechanisms involved in the mitogenic effect of lactoferrin in osteoblasts

    Bone

    (2011)
  • A. Grey et al.

    Lactoferrin potently inhibits osteoblast apoptosis, via an LRP1-independent pathway

    Mol. Cell. Endocrinol.

    (2006)
  • O. Johnell et al.

    An estimate of the worldwide prevalence and disability associated with osteoporotic fractures

    Osteoporos. Int.

    (2006)
  • R. Burge et al.

    Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025

    J. Bone Miner. Res.

    (2007)
  • C.L. Goldstein et al.

    Management of the elderly with vertebral compression fractures

    Neurosurgery

    (2015)
  • I. Sanli et al.

    Percutaneous cement augmentation in the treatment of osteoporotic vertebral fractures (OVFs) in the elderly: a systematic review

    Eur. Spine J.

    (2020)
  • L.X. Chen et al.

    Comparative efficacy and tolerability of three treatments in old people with osteoporotic vertebral compression fracture: a network meta-analysis and systematic review

    PloS One

    (2015)

    • Cited by (0)

    ‡

    The first two authors contributed equally to the work.

    View full text
    © 2021 The Society for Biotechnology, Japan. All rights reserved.